Alvotech has had a tough long term ride, and the current share price asks investors to judge whether the revenue behind the story is enough to support it. With so much of the recent experience tied to how sales can scale, the key issue is how the market price lines up with what the business actually sells today. Over the past 5 years the stock has fallen 50.9%, which puts the focus firmly on whether the current valuation still lines up with the company’s sales base. For a business built...
Alvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that members of the management team will participate in upcoming investor conferences in November as follows: UBS Global Biopharma Conference in London– fireside chat Tuesday, November 17 at 14:00 GMT (9:00 am ET).2026 Jefferies Global Healthcare Conference in London – presentation
REYKJAVIK, Iceland, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the nine months and third quarter ended September 30, 2026 on Wednesday, November 11, 2026, after the U.S. market close. The Company will also host a webcast with a live Q&A on Thursday, November 12, 2026,
Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.
Detailed price information for Alvotech (ALVO-Q) from The Globe and Mail including charting and trades.
Alvotech (ALVO) has meaningful stock recovery potential as manufacturing progress boosts confidence
Alvotech (ALVO) stock gains as the FDA OKs new manufacturing process for Simlandi, the company's Humira biosimilar marketed with Teva (TEVA). Read more here.
Investing.com -- Alvotech shares rose more than 6% in premarket trading Tuesday after the U.S. Food and Drug Administration approved a new manufacturing process for Simlandi, the company’s biosimilar to Humira.
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech’s biosimilars portfolio REYKJAVIK, Iceland and LONDON, UK (October 20, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announcedthat the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alv
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for patients with retinal diseases REYKJAVIK, Iceland and LONDON, UK (October 14, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma Holdco Limited
Detailed price information for Relay Therapeutics Inc (RLAY-Q) from The Globe and Mail including charting and trades.
Detailed price information for Alvotech (ALVO-Q) from The Globe and Mail including charting and trades.
Alvotech (NasdaqGM:ALVO) is back in focus after two closely timed manufacturing updates that reshape how its biosimilars could be supplied to major markets. Both moves revolve around capacity, regulatory readiness, and long term supply security. Recent trading shows that Alvotech has been back on investors’ radar, with a 30-day share price return of 9.96% and a 90-day move of 76.20% pointing to building momentum around the manufacturing updates, even though the 1-year total shareholder return...
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support growth in demand REYKJAVIK, Iceland, and SEOUL, South Korea (October 6, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and LOTTE Biologics, a contract developmen
Detailed price information for Alvotech (ALVO-Q) from The Globe and Mail including charting and trades.
Investing.com -- Alvotech SA (NASDAQ:ALVO) shares jumped 13.5% Monday after the U.S. Food and Drug Administration approved a supplement to the Biologics License Application for AVT02, enabling the company to manufacture the drug substance in a second production suite at its Reykjavik facility.
FDA approves SIMLANDI (ALVO) manufacturing expansion at Alvotech’s Reykjavik plant, confirming resolved inspections and boosting supply.
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the Reykjavik site REYKJAVIK, Iceland, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administrati
Detailed price information for Alvotech (ALVO-Q) from The Globe and Mail including charting and trades.
Alvotech (NASDAQ:ALVO) shares gained 5. 6% in premarket trading after Barclays upgraded the biosimilar drug developer from Underweight to Overweight and raised its price target from $4.
This is the newest page. Registered accounts read further back.